Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Development and challenges for T-cell engagers as a novel treatment for lung...

Dr May-Lucie Meyer - Lausanne University Hospital, Lausanne, Switzerland

Development and challenges for T-cell engagers as a novel treatment for lung cancer and mesothelioma ( Dr May-Lucie Meyer - Lausanne University Hospital, Lausanne, Switzerland )

Cemiplimab shows durable 6-year survival benefit in PD-L1 high advanced NSCLC

Dr Miranda Gogishvili - High Technology Medical Centre, Tbilisi, Georgia

Cemiplimab shows durable 6-year survival benefit in PD-L1 high advanced NSCLC ( Dr Miranda Gogishvili - High Technology Medical Centre, Tbilisi, Georgia )

MK-1084 plus pembrolizumab achieves high response rates in KRAS G12C mutated...

Dr Adrian Sacher - Princess Margaret Cancer Center, Toronto, CA

MK-1084 plus pembrolizumab achieves high response rates in KRAS G12C mutated non-small cell lung cancer ( Dr Adrian Sacher - Princess Margaret Cancer Center, Toronto, CA )

Durvalumab plus chemotherapy improves survival in extensive-stage small cell...

Dr Lorenza Landi - National Cancer Institute Regina Elena, Rome, Italy

Durvalumab plus chemotherapy improves survival in extensive-stage small cell lung cancer regardless of tumour laterality ( Dr Lorenza Landi - National Cancer Institute Regina Elena, Rome, Italy )

Durvalumab improves survival and delays progression in limited-stage small cell...

Dr Eva Buchmeier - Hospitals of the City of Cologne gGmbH, Cologne, Germany

Durvalumab improves survival and delays progression in limited-stage small cell lung cancer ( Dr Eva Buchmeier - Hospitals of the City of Cologne gGmbH, Cologne, Germany )

Osimertinib plus local therapy improves outcomes in EGFR-mutant metastatic lung...

Dr Saumil Ganhdi - University of Texas MD Anderson Cancer Center, Houston, USA

Osimertinib plus local therapy improves outcomes in EGFR-mutant metastatic lung cancer ( Dr Saumil Ganhdi - University of Texas MD Anderson Cancer Center, Houston, USA )

Pembrolizumab plus chemotherapy delivers lasting benefit in early-stage NSCLC

Dr Margarita Majem - Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

Pembrolizumab plus chemotherapy delivers lasting benefit in early-stage NSCLC ( Dr Margarita Majem - Hospital de la Santa Creu i Sant Pau, Barcelona, Spain )

Becotarug plus osimertinib shows survival benefit in EGFR exon 20 insertion...

Dr Jinhui Xue - Sun Yat-sen University Cancer Center, Guangzhou, China

Becotarug plus osimertinib shows survival benefit in EGFR exon 20 insertion lung cancer ( Dr Jinhui Xue - Sun Yat-sen University Cancer Center, Guangzhou, China )

TQB2922 combination shows high response rates in EGFR-mutant lung cancer after...

Dr Jinhui Xue - Sun Yat-sen University Cancer Center, Guangzhou, China

TQB2922 combination shows high response rates in EGFR-mutant lung cancer after tyrosine kinase inhibitor resistance ( Dr Jinhui Xue - Sun Yat-sen University Cancer Center, Guangzhou, China )

SHR-A2009 plus EGFR tyrosine kinase inhibitor shows promising activity in EGFR...

Prof Yi-Long Wu - Guangdong Lung Cancer Institute, Guangzhou, China

SHR-A2009 plus EGFR tyrosine kinase inhibitor shows promising activity in EGFR-mutant lung cancer ( Prof Yi-Long Wu - Guangdong Lung Cancer Institute, Guangzhou, China )

Subcutaneous amivantamab plus lazertinib shows durable responses in EGFR-mutant...

Prof Nicolas Girard - Institut Curie, Paris, France

Subcutaneous amivantamab plus lazertinib shows durable responses in EGFR-mutant advanced lung cancer ( Prof Nicolas Girard - Institut Curie, Paris, France )

T-cell engagers in lung cancer: Strategies to prevent and manage toxicities

Dr Myung-Ju Ahn - Sungkyunkwan University School of Medicine, Seoul, South Korea

T-cell engagers in lung cancer: Strategies to prevent and manage toxicities ( Dr Myung-Ju Ahn - Sungkyunkwan University School of Medicine, Seoul, South Korea )

More from ecancer